Skip to main content
. 2020 Dec 10;10:21762. doi: 10.1038/s41598-020-78646-y

Figure 1.

Figure 1

Mutations in the PI3K pathway are associated with poor overall survival for patients with HER2-positive (HER2+) and HER2 and ER double-positive (HER2+/ER+) breast cancer. (a) Overall survival (OS) was analyzed in patients with HER2+ breast cancer with (red) or without (blue) mutations in the PI3K pathway. Median OS was 115.3 (blue) vs 79.5 months (red), respectively (hazard ratio: 1.82; 95% CI 1.0–3.3, p value = 0.036). (b) OS was analyzed in patients with HER2+/ER+ breast cancer with (red) or without (blue) mutations in PI3K pathway. Median OS was 115.3 (blue) vs 79.0 months (red), respectively (hazard ratio: 2.10; 95% CI: 1.0–4.5, p value = 0.04).